Paper Details

  1. Home
  2. Paper Details

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

Author: AppelbaumF R, ChesonB D, EliasL, HinesJ, KolitzJ, LarsonR A, PetersonB L, RaiK R, SchifferC A, ShepherdL, ThreatteG A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study found that fludarabine yielded higher response rates and a longer duration of remission and progression-free survival than chlorambucil in patients with chronic lymphocytic leukemia.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial treatment with chlorambucil. We compared the efficacy of fludarabine with that of chlorambucil in the primary treatment of chronic lymphocytic leukemia. METHODS: Between 1990 and 1994...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM200012143432402

データ提供：米国国立医学図書館（NLM）

Fludarabine vs. Chlorambucil: Navigating the Treatment of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a type of cancer affecting white blood cells. This study compared the efficacy of two drugs, fludarabine and chlorambucil, in treating CLL patients who had not responded to prior treatments. The researchers aimed to determine which drug offered a better chance of achieving remission and extending survival.

Fludarabine Emerges as a More Effective Treatment Option

The results showed that fludarabine was significantly more effective than chlorambucil in achieving remission and prolonging progression-free survival. Patients treated with fludarabine experienced higher response rates, longer remission durations, and a median progression-free survival of 20 months, compared to 14 months for those receiving chlorambucil.

Choosing the Right Treatment for CLL: Balancing Effectiveness and Safety

While fludarabine demonstrated better efficacy, it also showed a higher frequency of side effects like infections and neutropenia. Choosing the appropriate treatment for CLL requires weighing the potential benefits and risks, considering the individual patient's needs and medical history.

Dr. Camel's Conclusion

The quest for effective CLL treatments is like a journey through a desert oasis. Fludarabine, like a refreshing spring, offers greater effectiveness in battling the disease. However, as with any oasis, there are potential challenges, such as side effects, that must be carefully considered. Ultimately, the best treatment for CLL is the one that best suits the individual patient's needs.

Date :
  1. Date Completed 2000-12-14
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

11114313

DOI: Digital Object Identifier

10.1056/NEJM200012143432402

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.